MONTREAL, QUEBEC--(Marketwired - May 27, 2013) - Theratechnologies (TH.TO) announced today that 121851 Canada Inc., the same petitioner who filed a motion in July 2010, filed a second motion of authorization to institute a class action against the Company, a director and a former executive officer. This second motion is based on the same facts and seeks the same conclusion as the first motion, except that damages are sought under the Civil Code of Quebec instead of the Securities Act (Quebec). This second motion was filed in the Superior Court of the province of Quebec, district of Montreal.
Even if this second motion is granted, the damages sought cannot be cumulated with the damages sought in the initial motion.
Theratechnologies is of the view that the allegations contained in this second motion are without merit and intends to take all appropriate actions to vigorously defend its position.
Theratechnologies (TH.TO) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the SEC's website at www.sec.gov.